Since 2020, our relationship with the Skye Bioscience team has spanned initial naming and brand identity, all the way to creating screen assets for their exciting approval announcement to list on the NASDAQ. With more still to come.
The Skye Bioscience team is leading the development of next-gen drugs to unlock new therapeutic pathways for metabolic health. To really understand the innovative science behind Skye’s work, Very Polite’s curiosity led to the team’s consistent re-engagement with Skye’s science and research experts. As external internals, the VP team discovered unexpected design systems inspired by the peripheral CB1inhibitor at the centre of Skye’s technology.